BioMed X Institute Announces Expansion of their Strategic Collaboration with Janssen in Immunology Research

Overview

• Post By : Kumar Jeetendra


• Source: Wire agencies


• Date: 09 Nov,2020

HEIDELBERG, Germany, November 09, 2020 / B3C newswire / — German independent research institute BioMed X adds a further research program in the field of immunology to their existing collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson: The new project will focus on the development of novel methodologies to systematically profile and dissect complex tissue microenvironments. The goal is to identify components that induce pro-resolution responses in tissue-resident innate immune cells to restore homeostasis in autoinflammatory diseases such as psoriasis, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or inflammatory bowel disease (IBD). The collaboration was facilitated by Johnson & Johnson Innovation.

Christian Tidona, Founder and Managing Director of BioMed X Institute: “We are excited to expand our collaboration with Janssen with a second research project in the field of autoimmune diseases. The new project offers a unique opportunity to develop novel therapeutic concepts and innovative approaches to tackle the most difficult-to-treat autoimmune diseases of our time.”
An emerging area of science is being focused on identifying strategies to treat patients with autoimmune diseases that not only block inflammation, but which promote pro-resolution responses in immune cells to restore homeostasis.

Recent research findings suggest that tissue factors released during cellular damage, stress or inflammation can trigger pro-resolution responses in innate immune cells without negatively impacting other cell types.

Further details about the call for application can be found on the website of the BioMed X Institute at www.bio.mx. Interested candidates are invited to apply at www.bio.mx/apply.